NYBCe and Biohub Partner to Create 'Universal' Stem Cells from Cord Blood

NEW YORK, NY – April 30, 2026 – In a move that could significantly accelerate the future of regenerative medicine, New York Blood Center Enterprises (NYBCe) and the research organization Biohub have launched a major scientific collaboration. The initiative aims to develop and standardize methods for creating powerful, next-generation stem cells from umbilical cord blood, potentially paving the way for 'off-the-shelf' cell therapies to treat a wide range of diseases.

The partnership will focus on deriving induced pluripotent stem cells (iPSCs) from specific immune cells isolated from donor-consented cord blood units. By combining NYBCe’s vast biological resources with Biohub’s cutting-edge cellular engineering expertise, the project seeks to overcome some of the most significant hurdles currently facing cell-based therapies, including immune rejection and manufacturing scalability.

A Strategic Synergy of Resource and Technology

At the heart of the collaboration is a powerful synergy between two leaders in their respective fields. NYBCe brings to the table its Lindsley F. Kimball Research Institute (LFKRI) and the National Cord Blood Program (NCBP), one of the world's largest and most diverse public cord blood banks with an inventory of over 30,000 clinically validated units. This provides an unparalleled, ethically sourced repository of starting material for the research.

Biohub, in turn, contributes its specialized expertise in reprogramming defined immune cell subsets into iPSCs. Their advanced techniques, which integrate artificial intelligence and synthetic biology, are designed not only to create stem cells but to do so while preserving the unique genetic signatures that encode specific immune functions. This effectively immortalizes the donor cells, creating a renewable resource for long-term research and therapeutic development.

“This collaboration brings together complementary strengths in cord blood biology and cellular engineering,” said Larry Luchsinger, Senior Vice President and Chief Scientific Officer at New York Blood Center Enterprises. “By combining NYBCe’s unparalleled cord blood biorepository and clinical consent infrastructure with the Biohub’s expertise in reprogramming and cell engineering, we are building a scalable platform that can accelerate discovery across immunology, regenerative medicine, and cell therapy.”

The sentiment is echoed by Biohub's leadership, who see the partnership as a force multiplier.

“NYBCe has built a consented, clinically validated cord blood biorepository at a scale that few institutions can match,” noted Sjoukje van der Stegen, a Senior Group Leader for Immune Cell Engineering & Development at Biohub. “Pairing that depth of resource with Biohub's immune cell reprogramming program creates an opportunity that neither organization could realize independently, and we believe the platforms emerging from this collaboration will have a significant and lasting impact across the field.”

The Science Behind 'Off-the-Shelf' Cell Therapy

The central scientific challenge in using donor cells for therapy is the immune system's natural tendency to attack anything it recognizes as 'foreign.' This is governed by a set of proteins on the cell surface called Human Leukocyte Antigens (HLA). A mismatch between a donor's and a recipient's HLA profile can lead to transplant rejection, a critical barrier for creating therapies that can be used on a broad population.

This collaboration aims to solve that problem by leveraging a unique asset within NYBCe's biobank: cord blood units from donors who are homozygous for certain HLA genes. A person with a homozygous HLA profile has inherited identical HLA markers from both parents. Stem cells derived from these donors express fewer distinct HLA types, making them a much closer match for a significantly larger percentage of the population.

These homozygous HLA-iPSC lines function as a kind of 'master key,' creating a foundation for 'broadly compatible' or 'universal donor' cell lines. Such cells would be less likely to trigger an immune response, dramatically reducing the risk of rejection. This would enable the development of 'off-the-shelf' therapies that could be manufactured at scale, stored, and administered to patients on demand, eliminating the costly and time-consuming process of creating custom therapies from each patient's own cells.

Biohub's focus on reprogramming specific immune cell populations adds another layer of sophistication. By preserving the functional programming of these cells, the resulting iPSCs could be more efficiently directed to become specialized therapeutic cells, such as T-cells engineered to hunt cancer or regulatory cells designed to quell autoimmune attacks.

Engineering a New Frontier in Disease Treatment

The potential applications for these broadly compatible iPSC lines are vast and transformative. While the development and clinical approval process is lengthy, the foundational platform being built could fuel breakthroughs in some of medicine’s most challenging areas for years to come.

Biohub's primary mission includes engineering immune cells to act as 'cellular endoscopes'—living sensors that can patrol the body, detect the earliest signs of disease, and even deliver targeted treatments. This approach is being aimed at notoriously difficult-to-detect cancers, such as ovarian and pancreatic cancer, where early diagnosis is critical for survival.

Beyond oncology, the impact could be profound across regenerative medicine. The ability to generate an unlimited supply of healthy, compatible cells opens the door to treating a host of conditions characterized by cell damage or loss:

• Neurodegenerative Diseases: iPSC-derived neurons or support cells could be used to replace cells lost in conditions like Parkinson's and Alzheimer's disease, potentially restoring function or slowing disease progression.
• Cardiology: Cardiomyocytes grown from iPSCs could be used to repair heart muscle damaged by a heart attack.
• Diabetes: The generation of insulin-producing pancreatic beta cells could offer a functional cure for Type 1 diabetes.

Even before these therapies reach the clinic, the iPSC lines will serve as an invaluable shared resource for the global research community. They will enable the creation of highly accurate 'disease-in-a-dish' models, allowing scientists to study disease mechanisms and test new drugs with unprecedented speed and precision.

Charting a Course in a Competitive Field

The quest for universal donor stem cells is a 'holy grail' in biotechnology, and the NYBCe-Biohub partnership is entering a dynamic and competitive landscape. Other research groups and companies are pursuing similar goals, often using different technologies like CRISPR gene editing to 'cloak' cells from the immune system by deleting their HLA markers.

The distinct advantage of this collaboration lies in its strategy. Rather than relying solely on genetic engineering to create a universal cell, it leverages a naturally occurring biological advantage—the homozygous HLA profile—found within NYBCe's massive, ethnically diverse biobank. This, combined with a multi-phase plan to create standardized, reproducible workflows, is not just about creating a single cell line, but about building a robust and scalable platform for generating them.

By establishing definitive protocols and sharing the resulting iPSC lines as foundational research tools, the collaboration aims to elevate the entire field. The project represents a long-term investment in building the infrastructure needed for the next generation of medicine, where treatments are not just discovered, but systematically engineered. This validated approach to generating immune cell-derived iPSC resources from cord blood is poised to support foundational research and translational development for many years ahead.